GenomeWeb’s Pharmacogenomics Reporter discussed GeneDx’s decision to file for inter partes review (IPR) of 11 patents held by, or licensed to, Myriad Genetics. Turna Ray reports that IPR of these 11 patents would require the USPTO to determine whether or not prior art undermines certain patent claims. Sterne, Kessler, Goldstein & Fox filed these IPRs on behalf of GeneDx.
To read the full article, click here.
Related Professionals
Stay in the Know
Receive insights from the most respected practitioners of IP law, straight to your inbox.
Subscribe for Updates